NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/23/2024
Back to search
Official data from USPTO
DEXCEL PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
DEXCEL PHARMA
ST13
US500000097721524Class
5
Filing
97721524
Registration
7453088
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
07/23/2024
Trademark type
Word
Nice classes
5
Filing date
12/16/2022
Registration date
07/23/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/23/2024
Last transaction
07/23/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
2000-09-00
First use in commerce
2000-09-00
Drawing code
4
Owner type
16
Owner location
Jerusalem, IL
Examiner
SPARACINO, MARK
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
DEXCEL PHARMA TECHNOLOGIES LTD.
Representatives
Sebastian Lovera Ladas & Parry LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
House mark for a full line of pharmaceutical preparations and medicines
Publications
History of USPTO decisions and trademark events.
27 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/23/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/07/2024
PUBO
PUBLISHED FOR OPPOSITION
05/07/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/17/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/02/2024
DOCK
ASSIGNED TO EXAMINER
03/14/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/28/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/27/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/27/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
10/30/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
10/30/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/31/2023
GNRT
NON-FINAL ACTION E-MAILED
07/31/2023
CNRT
NON-FINAL ACTION WRITTEN
07/31/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/21/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/21/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/21/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/03/2023
GNRT
NON-FINAL ACTION E-MAILED
04/03/2023
CNRT
NON-FINAL ACTION WRITTEN
04/03/2023
DOCK
ASSIGNED TO EXAMINER
03/23/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/13/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/20/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/20/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/20/2022
NWAP
NEW APPLICATION ENTERED
12/20/2022
Continuous trademark protection
Get notified about every new filing that threatens DEXCEL PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.